CAR-T therapy in ALL by Eolia Brissot in the 8th IACH Annual Meeting Mohamad Mohty Uriel Suárez IACH

Does remission after CAR-T therapy re places allo-HSCT in R/R ALL? by Eolia Brissot Mohamad Mohty Uriel Suárez IACH

Ayer se cumplieron 44 años del estreno de “D’Artacán y los tres Mosqueperros”. Pocas series más míticas que esta, a la que volver una y otra vez, en especial, por sus valores❤️ Feliz viernes, mi gente de CINE😎😍❤️🙌🏼

Myelofibrosis: ongoing trials of JAKi combinations and emerging therapies Mohamad Mohty Uriel Suárez IACH

8th Annual Meeting of the IACH: defining MDS/MPN entities for clinical decision making by Daniel Wiseman Dr Daniel N. Wiseman Mohamad Mohty Uriel Suárez IACH

Insights in the CMML molecular landscape by Laura Palomo. I am curious about the role of PHF6 status mutation in the molecular taxonomy and prognosis Mohamad Mohty Uriel Suárez IACH

More about MDS/MPN syndromes. Some schemes about transplant decisions in CMML and MDS/MPN and ongoing clinical trials by Francesco Onida Mohamad Mohty Uriel Suárez IACH

A nice presentation by Marco Raddy about the selection of patients for ESA therapy Mohamad Mohty Uriel Suárez IACH

🔴 Sesión plenaria con las 6️⃣ mejores comunicaciones presentadas al Congreso Nacional #Hemato2025. ¡Enhorabuena a los seleccionados! 🎖️Un congreso en el que de nuevo, se bate récord, con 1.060 comunicaciones aceptadas ⬇️⬇️⬇️📸📸🧵 📃SCORE POR INTELIGENCIA ARTIFICIAL PARA EL

Hace 39 AÑOS se estrenaba el anime SAINT SEIYA, también conocido como «Los Caballeros del Zodiaco». ✨ El opening es Pegasus Fantasy. 🔥 #Anime

CAR-T and bispecifics are powerful, life-prolonging tools, but their success depends heavily on timing, disease context, and the ability to debulk beforehand. The field truly needs innovation beyond the current immunotherapy paradigm.

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study Blood Cancer Journal nature.com/articles/s4140…

With marginal PFS benefit over a delinquent control arm (which could very well be an artifact of censoring (PMID: 40631771), no OS benefit thus far, and the broader/evolving landscape of regimens in relapse with 1-3 prior lines, I can't imagine using Seli-Vd in any of my patients

Long-term follow-up of the Baltimore experience with hematopoietic cell transplantation for severe aplastic anemia using post-transplant cyclophosphamide Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

Methionine dependency is the Achilles' heel of the very aggressive KMT2A-rearranged pediatric acute lymphoblastic leukemia: the orally active methionine adenosyltransferase 2A inhibitor FIDAS-5 can block it. haematologica.org/article/view/1…

📢 𝘚𝘵𝘢𝘺 𝘤𝘰𝘯𝘯𝘦𝘤𝘵𝘦𝘥 𝘸𝘪𝘵𝘩 IACH — 𝘯𝘰𝘸 𝘰𝘯 𝘞𝘩𝘢𝘵𝘴𝘈𝘱𝘱! 𝗪𝗲’𝗿𝗲 𝗲𝘅𝗰𝗶𝘁𝗲𝗱 𝘁𝗼 𝗹𝗮𝘂𝗻𝗰𝗵 𝘁𝗵𝗲 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹 𝗜𝗔𝗖𝗛 𝗪𝗵𝗮𝘁𝘀𝗔𝗽𝗽 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 🎉 📲 𝘎𝘦𝘵 𝘲𝘶𝘪𝘤𝘬 𝘶𝘱𝘥𝘢𝘵𝘦𝘴 𝘰𝘯: ✅ 𝘐𝘈𝘊𝘏 𝘦𝘷𝘦𝘯𝘵𝘴, 𝘨𝘳𝘢𝘯𝘵𝘴 &

#Myeloma Paper of the Day: US population-based analysis of smoldering myeloma finds 76% 5-year OS (2016-2019) vs. 50.5% for symptomatic myeloma; lowest in pts ≥80 years & in Hispanics, highest in Black vs. White & other races, highest in East: pubmed.ncbi.nlm.nih.gov/41213002/. #mmsm

🔥🧬 Breaking With 50 Years of AML Treatment Traditions — Tweet Summary (Emojis) (Dr. Naval Daver — AML 2025 Updates) 🔴 APL • 🎉 Cure rate >90% • 💊 ATRA + ASO203 🔵 CBF-AML • 🎉 Cure rate >80% • 💥 FLAG-GO 💪 Young/Fit AML • 🚀 More intensive than 3+7 • ⭐ FLAG-IDA +

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 Blood Journals Portfolio ashpublications.org/blood/article/…

Summary slides from Dr Yesid from #MdAnderson about acute leukemias treatment #ACHO